(Yicai Global) Feb. 7 -- Dutch regulators have greenlighted a drug Poly Pharm Co. makes that treats acute coronary syndrome.

The company has won drug marketing authorization for eptifibatide injections from the Netherlands Medicines Evaluation Board, the drug maker headquartered in China's southernmost Hainan province announced yesterday.

Eptifibatide is a platelet glycoprotein IIb/IIIa receptor antagonist able to reverse the ischemic condition thrombosis causes. It treats acute coronary syndrome, per the announcement.

Originally developed by COR Therapeutics Inc., Eptifibatide injection secured approval to enter the US market in May 1998. It got the nod to enter the EU market in July 1999 under the tradename INTEGRILIN, and is now widely available worldwide, public data show.